STOCK TITAN

Akari Therapeutics Plc - AKTX STOCK NEWS

Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.

Akari Therapeutics Plc (AKTX) is a clinical-stage biopharmaceutical company advancing innovative treatments for rare autoimmune and inflammatory diseases. This page provides investors and industry observers with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.

Access comprehensive coverage of AKTX’s progress, including press releases on trial results, FDA designations, and partnership announcements. Our curated news collection focuses on developments related to coversin, nomacopan, and other pipeline candidates targeting complement-mediated disorders.

Key updates include progress in treating conditions like HSCT-TMA and Geographic Atrophy, manufacturing partnerships, and scientific presentations. All content is verified from primary sources to ensure accuracy for investment research and market analysis.

Bookmark this page for centralized access to AKTX’s latest developments in complement system therapeutics. Check regularly for objective updates on clinical advancements and corporate announcements relevant to biopharmaceutical investors.

Rhea-AI Summary

The 'Asthma Pipeline Insight – 2023' report by DelveInsight reveals a dynamic landscape in asthma therapies, highlighting over 90 active pharmaceutical players developing more than 95 pipeline treatments. Key companies include GlaxoSmithKline, AstraZeneca, and Verona Pharma. Notably, dexpramipexole received an Innovation Passport from the UK's MHRA and is entering Phase III trials. Additionally, Pulmatrix, Inc. initiated a Phase IIb trial for PUR1900, targeting Allergic Bronchopulmonary Aspergillosis. Olatec Therapeutics secured $40 million in Series A funding to advance dapansutrile into clinical development. This report offers insights into asthma clinical trials, therapeutic assessments, and drug mechanisms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) has made significant strides in its Phase 3 Part A clinical trial of nomacopan for pediatric HSCT-related thrombotic microangiopathy (HSCT-TMA). A case study presented on February 16 at a major transplantation conference highlighted the positive outcomes for a 6-year-old patient who showed improvement after receiving nomacopan treatment.

Notably, the patient achieved critical therapeutic milestones, including normalization of key biomarkers and resolution of related health complications. Nomacopan is recognized as a promising therapy in a field lacking approved options for severe cases, potentially addressing an 80% mortality rate in untreated patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.73%
Tags
-
Rhea-AI Summary

Akari Therapeutics announced progress on its pre-clinical program for long-acting PAS-nomacopan, targeting geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). An Investigational New Drug (IND) application is set for submission to the FDA in the first half of 2024. The company filed a composition of matter patent application for long-acting versions, providing protection until 2042. The new PAS-nomacopan versions exhibit significant improvements, allowing for increased dosing intervals beyond three months, potentially reducing the need for frequent intravitreal injections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) has announced the progression into Part B of its Phase 3 clinical trial for nomacopan, targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Following favorable FDA feedback indicating that pharmacokinetic/pharmacodynamic data from Part A aligns with predictions, Akari will advance its study for patients aged 2 to <18 years. To support this, a new pipeline program for adult HSCT-TMA treatment with nomacopan is being initiated, given the larger adult patient population. The company's prompt actions highlight a commitment to addressing unmet medical needs in both pediatric and adult demographics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary

The paroxysmal nocturnal hemoglobinuria (PNH) market is projected to reach USD 1,100 million in 2021, with anticipated growth driven by rising cases and new therapies from major companies like Hoffmann-La Roche, Alexion, and Novartis. DelveInsight's report indicates approximately 12K prevalent cases in the 7MM (U.S., EU-4, U.K., Japan) as of 2021. Key pipeline therapies include Crovalimab and Iptacopan. Despite advancements, challenges like continuous hemolysis and the impending expiration of eculizumab patents in 2024 and 2027 could impact market dynamics. This report covers market trends through 2032, focusing on treatment efficacy, barriers, and emerging drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary

On January 4, 2023, Akari Therapeutics (Nasdaq: AKTX) announced that President and CEO Rachelle Jacques will present at the Biotech Showcase 2023 on January 9 at 9 am ET. The presentation will cover significant updates on two pipeline programs: a Phase 3 trial of nomacopan for treating severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program for long-acting PAS-nomacopan targeting geographic atrophy. Akari is focused on therapies for autoimmune and inflammatory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
conferences
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX), a biotechnology firm, announced participation in the Cantor Medical and Aesthetic Dermatology Conference in Miami on December 7-8, 2022. President and CEO Rachelle Jacques will join an ophthalmology panel on December 8, discussing 'Vision for the Future: Dry AMD, Other Greenfield Opportunities, and Late-Stage Stories to Shake Things Up.' The management team will also conduct 1:1 investor meetings to address their pre-clinical program for long-acting PAS-nomacopan in geographic atrophy (GA). Akari's investigational drug, nomacopan, targets autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
conferences
-
Rhea-AI Summary

Akari Therapeutics, Plc (Nasdaq: AKTX) announced participation in BTIG's Ophthalmology Day on November 29, 2022, with a fireside chat led by CEO Rachelle Jacques at 9:30 am ET. The company will discuss advancements in long-acting PAS-nomacopan for geographic atrophy (GA), highlighting positive pre-clinical results that may support moving towards IND/IMPD for clinical trials. Akari is focused on developing therapies for autoimmune and inflammatory diseases, with its lead candidate, nomacopan, having received several FDA designations for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
conferences
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) announced that the FDA granted Rare Pediatric Disease Designation to its investigational drug, nomacopan, for treating pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). This designation complements the existing Orphan Drug and Fast Track designations. The CEO emphasized the urgent need for effective treatments, highlighting the high mortality rates associated with the condition. The FDA's designation also offers potential benefits, including eligibility for a Priority Review Voucher upon approval of nomacopan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX), a biotechnology firm focused on autoimmune and inflammatory diseases, will attend the Jefferies London Healthcare Conference from November 15-17, 2022. Rachelle Jacques, President and CEO, along with the management team, will hold one-on-one meetings with registered investors. The company is advancing its lead product, nomacopan, which targets severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and is also exploring long-acting formulations for geographic atrophy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
conferences
Akari Therapeutics Plc

Nasdaq:AKTX

AKTX Rankings

AKTX Stock Data

34.80M
13.69M
44.7%
1.35%
0.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON